Spectrum Pharmaceuticals, Inc.
POZIOTINIB COMBINATIONS WITH AN ANTI-HER1, HER2 OR HER4 ANTIBODY AND METHODS OF USE THEREOF

Last updated:

Abstract:

Provided are combinations of poziotinib and an anti-HER1, anti-HER2 or anti-HER4 antibody, optionally with other agents, and use of the combinations for treating cancer.

Status:
Application
Type:

Utility

Filling date:

25 Jun 2019

Issue date:

26 Aug 2021